Prophylix Pharma AS is a Scandinavian biotech company headquartered in Tromsø, Norway, and the owner of its US subsidiary Prophylix Pharma Inc.
Prophylix is developing new prophylaxes that protect babies at risk from fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is a condition that can lead to severe brain damage and death.
Prophylix was established in 2008 by Norinnova Technology Transfer AS, the University Hospital of North Norway (UNN, Tromsø) and Oslo University Hospital (Ullevaal). The scientific basis of this company is a collaborative research activity conducted by scientists at the universities and University Hospitals in Oslo and Tromsø.